Ishizaka Y, Yamamoto Y, Fukunaga T, Yokota N, Kida O, Kitamura K, Kangawa K, Minamino N, Matsuo H, Eto T
First Department of Internal Medicine, Miyazaki Medical College, Japan.
Am J Kidney Dis. 1994 Sep;24(3):461-72. doi: 10.1016/s0272-6386(12)80903-6.
The plasma concentration of immunoreactive human brain natriuretic peptide (ir-BNP) was measured in 40 patients on hemodialysis (HD) and in 12 healthy subjects. Immunoreactive human atrial natriuretic peptide (ir-ANP) was also measured. The mean (+/- SE) plasma ir-BNP concentration in the patients before HD (18.4 +/- 3.4 fmol/mL) was markedly higher than that in the control group (0.39 +/- 0.08 fmol/mL). The plasma ir-BNP level was significantly decreased by HD from 18.4 +/- 3.4 fmol/mL to 10.5 +/- 2.2 fmol/mL (P < 0.001), but the latter value was still higher than the upper limit of the normal range for our laboratory. There were significant correlations between the plasma ir-ANP level and the mean blood pressure before HD (P < 0.05) and between the HD-induced changes in plasma ir-ANP level and mean blood pressure (P < 0.001). These correlations were not observed between the plasma ir-BNP level and mean blood pressure. The plasma ir-BNP level correlated with the cardiothoracic ratio and this correlation was closer to that between the plasma ir-ANP level and cardiothoracic ratio. Ultrasound echocardiographic studies in 13 patients revealed that the pre-HD state of high cardiac output was correlated by HD in association with decreases in plasma ir-BNP and ir-ANP levels. Correlations were observed between the pre-HD ir-ANP level and the interventricular septal thickness index (r = 0.68, P < 0.05) and between the change in ir-BNP level and that in left atrial diameter (r = 0.806, P < 0.001). In conclusion, BNP levels were high in HD patients compared with the control subjects and were decreased during HD. In addition, BNP and ANP levels correlated with several parameters of volume change and cardiac status.
对40例接受血液透析(HD)的患者及12名健康受试者测定了免疫反应性人脑钠肽(ir-BNP)的血浆浓度。同时也测定了免疫反应性人心房钠肽(ir-ANP)。HD治疗前患者的血浆ir-BNP平均浓度(18.4±3.4 fmol/mL)显著高于对照组(0.39±0.08 fmol/mL)。HD治疗后血浆ir-BNP水平从18.4±3.4 fmol/mL显著降至10.5±2.2 fmol/mL(P<0.001),但后者仍高于本实验室正常范围上限。HD治疗前血浆ir-ANP水平与平均血压之间存在显著相关性(P<0.05),HD治疗引起的血浆ir-ANP水平变化与平均血压之间也存在显著相关性(P<0.001)。血浆ir-BNP水平与平均血压之间未观察到这些相关性。血浆ir-BNP水平与心胸比率相关,且这种相关性比血浆ir-ANP水平与心胸比率之间的相关性更密切。对13例患者进行的超声心动图研究显示,HD治疗前的心输出量高状态与HD治疗后血浆ir-BNP和ir-ANP水平降低相关。HD治疗前ir-ANP水平与室间隔厚度指数之间存在相关性(r = 0.68,P<0.05),ir-BNP水平变化与左心房直径变化之间也存在相关性(r = 0.806,P<0.001)。总之,与对照组相比,HD患者的BNP水平较高,且在HD治疗期间降低。此外,BNP和ANP水平与容量变化和心脏状态的几个参数相关。